newsfilter
← Latest News
GlobeNewswire·

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1